AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product candidate AZD5004 achieved weight loss of 5.8% in Type 2 diabetes ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

AstraZeneca PLC shed £15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company UK:AZN said its lead product ...

after gaining as much as 8.5% in New York on promising early-stage data. Those shares fell as Astra presented data on another pill that showed similar weight-loss benefits. Shares of obesity-shot ...

Viking shares fell 13% on Monday, their biggest loss since March, after Astra presented data on its pill that showed similar weight-loss benefits ... at Amgen Inc before becoming an analyst ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from ... as much as 2.9 per cent to a session high after the data release, before paring some gains. At 15.30 GMT they ...

and persistent effects in terms of weight loss (up to -8.3% from baseline) were also observed on the 57th day of follow-up, 4 weeks after the administration of the last pill. Based on a ...

VK2735, which is being developed in both as an injectable and in pill form ... showing a patient's average loss of 8.2% of their body weight after 28 days. While weight loss results from Zepbound ...